MediWound

MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » Altro su de.investing.com

A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » Altro su de.investing.com

MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » Altro su de.investing.com